Association Between Preoperative Myocardial Perfusion Imaging and Cardiac Events

1

23

2 after Elective Noncardiac Surgery 3 4 Seong-Bong Wee, MD, ¹ Cheol Hyun Lee, MD, ² Tae Joon Jun, PhD, ³ Jung-Min Ahn, MD, ¹ 5 Jeong Hwan Yook, MD, ⁴ Jae-Sik Nam, MD, ⁵ In-Cheol Choi, MD, ⁵ Dae Hyuk Moon, MD, ⁶ 6 Sangwon Han, MD, Hoyun Kim, MD, Yeonwoo Choi, MD, Jinho Lee, MD, Sangyong 7 Cho, MD, ¹ Tae Oh Kim, MD, ¹ Do-Yoon Kang, MD, ¹ Pil Hyung Lee, MD, ¹ Duk-Woo Park, 8 MD, ¹ Soo-Jin Kang, MD, ¹ Seung-Whan Lee, MD, ¹ Young-Hak Kim, MD, ¹ Cheol Whan Lee, 9 MD, Seong-Wook Park, MD, David J Cohen, MD, and Seung-Jung Park, MD. 10 11 ¹Division of Cardiology, Heart Institute, Asan Medical Center, University of Ulsan, Seoul, 12 Korea; ²Division of Cardiology, Department of Internal Medicine, Keimyung University 13 14 Dongsan Hospital, Daegu, Korea; ³Big Data Research Center, Asan Institute for Life 15 Sciences, Asan Medical Center, Seoul, Korea; ⁴Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; ⁵Department of Anesthesiology and 16 17 Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; ⁶Department of Nuclear Medicine, Asan Medical Center, University of Ulsan, College of 18 Medicine, Seoul, Korea; ⁷Department of Cardiology, Saint Francis Hospital and 19 20 Cardiovascular Research Foundation, NY, NY 10019, USA. 21 22 The first two authors (SB Wee and CH Lee) equally contributed to this paper.

- 24 Abstract Word Count: 290
- 25 Main Text Word Count: 2942
- 27 Address for correspondence:
- 28 Jung-Min Ahn, MD

- 29 Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine,
- 30 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea
- 31 Telephone: +82-2-3010-5904
- 32 Fax: +82-2-487-5918
- 33 E-mail: drjmahn@gmail.com

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

Abstract Background There remains a lack of robust evidence regarding the prognostic value of myocardial perfusion imaging (MPI) before noncardiac surgery in large and diverse patient populations. Methods This retrospective observational cohort study from single, tertiary, high surgical volume center in South Korea included 82,441 patients aged >40 years who underwent MPI using pharmacologic stress single photon emission computed tomography within 6 months before elective noncardiac surgery from January 2000 to December 2021. Results of MPI were classified as abnormal (any fixed or reversible perfusion defect) vs normal MPI before noncardiac surgery. The primary outcome was a composite of cardiac death or myocardial infarction within 30 days. **Results** Among the 82441 patients (mean±standard deviation age, 65.7±9.6 years; 47417 [57.5%] men), 184 (0.2%) experienced cardiac death or myocardial infarction within 30 days after noncardiac surgery. MPI were abnormal in 5603 patients (6.8%). Compared with a normal MPI, an abnormal MPI had a higher risk of the primary outcome (crude incidence, 1.2% vs 0.1%; adjusted odds ratio, 4.64; 95% confidence interval, 3.29-6.50; P<.001). The presence of an abnormal MPI improved discrimination for the primary outcome (area under the receiver operating characteristic curve with MPI vs without MPI (0.77 vs 0.73; P < 0.001))and significantly increased net reclassification improvement (0.26; 95% confidence interval, 0.11-0.40; P<.001). Among patients with an abnormal MPI, 378 (6.7%) underwent preoperative coronary revascularization; however, this was not associated with a lower risk of the primary outcome (P=.56).

Conclusion An abnormal myocardial perfusion imaging appeared to be an important risk

- 57 factor for adverse postoperative events and provided additional prognostic value for patients
- 58 undergoing noncardiac surgery. Nevertheless, preoperative MPI was limited by its low
- 59 positive predictive value for postoperative cardiac events, leading to potentially unnecessary
- 60 coronary revascularization procedures with unproven prognostic value.

Clinical Perspectives

What is new?

61

62

63

64

65

66

67

68

69

70

71

- This study included the largest population to date and included a broad spectrum of
 patient and surgical procedures compared with previous studies limited by relatively
 small sample sizes and low event rates.
- Preoperative abnormal MPI results were significantly associated with the
 postoperative risk of cardiac death and myocardial infarction in patients undergoing
 noncardiac surgery, and provided incremental prognostic value beyond clincial
 assement only.

What are the clinical implications?

- Our study suggested that MPI appears warranted, particularly for patients with a considerable surgical risk.
- However, its low positive predictive value, and unproven prognostic value of
 coronary revascularization triggered by MPI should be taken into account in the
 clincial practice.

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

Introduction Every year, \geq 200 million adults undergo major noncardiac surgery and its number is still increasing. ^{1,2} Despite the overall safety of contemporary noncardiac surgery, approximately 10% of these patients experience post-operative complications.³ Cardiovascular complications remain the leading cause of death within 30 days of noncardiac surgery.⁴ Therefore, identification of patients at high cardiovascular risk during preoperative consultation is important. Previous studies have revealed that abnormal features upon myocardial perfusion imaging (MPI) indicate an increased risk of perioperative cardiac complications. 5 Current practice guidelines recommend stress MPI prior to non-cardiac surgery for patients with both elevated risk of major adverse cardiac events and poor functional capacity especially if testing impacts decision-making or perioperative care. ⁴ The uncertain value of pre-operative MPI derives from its low diagnostic yield, the unclear clinical benefit of preoperative revascularization triggered by its results, and the potential for unnecessary delays of surgical treatment. ^{6,7} Notably, previous studies on preoperative MPI were limited by their small samples and numbers of events. Most studies were performed on the highest-risk patients (eg, those undergoing vascular surgery) decades ago, and the application of those results in today's practice is unclear, given advances in both surgery and perioperative care. In addition, the predictive discrimination associated with MPI has not been adequately compared with those derived from preoperative risk calculators alone. Nevertheless, preoperative MPI and subsequent revascularization are frequently performed in real-world practice to evaluate cardiac risk in an effort to prevent perioperative cardiac complications. 10-12

To address these gaps in contemporary evidence, we performed a retrospective, real-

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

Appendix.

world study: (1) determine the prognostic value of preoperative MPI to predict cardiac events after elective noncardiac surgery; and (2) examine the clinical benefit of selective coronary angiography and revascularization in response to abnormal MPI. Methods Study Design and Study Population This was a single-center, retrospective observational cohort study, and was conducted using data from the Asan Biomedical Research Environment (ABLE), which is a de-identified clinical database of Asan Medical Center, a 2700-bed tertiary hospital in Seoul, South Korea. This data warehouse contains all medical records of our center, including electronic medical records, international classification of disease codes, laboratory findings, imaging data, and medications in an anonymized form.¹³ The study population was drawn from all patients who underwent MPI in the 6 months prior to elective noncardiac surgery under general anesthesia between January 2000 and December 2021. Patients were excluded if they met any of the following criteria: younger than 40 years of age; undergoing an emergency operation; experiencing acute myocardial infarction in the month before surgery; undergoing cardiac surgery; undergoing nonsurgical procedures (eg, bronchoscopy, endoscopy, cystoscopy, and percutaneous vascular or nonvascular procedures); undergoing minor surgery with minimal sedation or local anesthesia, such as skin, dental, and ophthalmologic procedures. Only the index procedure of patients undergoing multiple eligible procedures during the study period was used for analyses. Additional inclusion and exclusion criteria are summarized in the Supplement

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

This study conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the institutional review board of Asan Medical Center. The need for written informed consent was waived. No industry was involved in the design, conduct, or analysis of the study. **Data Extraction and Collection** Patient demographics, comorbidities, prescriptions, laboratory data, types of surgeries, and outcomes were obtained via the ABLE system by researchers who were blinded to the process of data analysis. Comorbidities diagnosed prior to the date of noncardiac surgery were electronically obtained using the Korean Standard Classification of Diseases and Causes of Death (KCD-7), which was developed based on the International Classification of Diseases, 10th revision (Supplement). ¹⁴ In addition, the revised cardiac risk index (RCRI), which consists of six identifiable predictive factors (high-risk surgery [intraperitoneal, intrathoracic, and suprainguinal vascular surgery], ischemic heart disease, congestive heart failure, cerebrovascular disease, diabetes mellitus controlled with insulin therapy, and renal dysfunction [serum creatinine concentration >2.0 mg/dL]), was calculated. All 1436 types of surgeries performed in the study population were reviewed and classified as low- or high-risk surgeries based on prior expert consensus (Supplement Appendix). 15,16 **Myocardial Perfusion Imaging** Single photon emission computed tomography with thallium-201 (Tl-201) was used to acquire myocardial perfusion images via a standardized protocol, as previously described.¹⁷ Pharmacologic stress was induced with intravenous infusion of either adenosine (0.14

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

mg/kg/min for 6 min) or dipyridamole (0.56 mg/kg/min for 4 min). At peak stress, a 44.4— 148.0-MBq dose of 201-Tl was intravenously injected, depending on the patient's body weight and the type of gamma camera used. Post-stress and redistribution MPIs were acquired with one of the following camera systems equipped with a conventional Anger camera or cadmium-zinc-telluride detectors: Triad 88 or XLT (Trionix Research Laboratory, Twinsberg, OH, USA); ADAC or Precedence 16 (Philips Healthcare, Best, The Netherlands); E.Cam, Symbia T2, or Evo Excel (Siemens Healthineers, Erlangen, Germany); Infinia, Ventri, Discovery NM830, or NM530c (GE Healthcare, Waukesha, WI, USA). Specific acquisition parameters depended on the type of camera. MPI was primarily analyzed qualitatively by experienced nuclear medicine physicians (D.H.M. and S.W.H) as a normal or abnormal. ¹⁷ Subsequently, abnormal results were further classified into fixed perfusion defects only or any reversible perfusion defect. In addition, semi-quantitative analysis, performed using a 20-segment model and a five-point scale, was used to calculate the summed stress score, summed rest score, and summed difference score (SDS). The SDS was converted into a percentage of total myocardium by dividing it by the maximum potential score (4×20) to assess the ischemic burden (% ischemic mvocardium). 18,19 **Study Outcomes and Follow-up** The primary outcome in this study was the composite of cardiac death or myocardial infarction within 30 days after elective noncardiac surgery. Cardiac death was defined as sudden death or death secondary to a proximate cardiac cause, including cardiac arrest, myocardial infarction, low-output failure, or fatal arrhythmia. Myocardial infarction was

defined as an elevation of cardiac enzymes with associated signs and symptoms of ischemia felt to be caused by coronary atherothrombosis. The secondary outcomes were cardiac death, all-cause death, and myocardial infarction within 30 days after elective noncardiac surgery. The mortality data was confirmed by cross-referencing with the Korean National Health Insurance Service, which is a single-payer program of a universal health coverage system and mandatory health care in Korea. In addition, all medical records and other source documents were carefully reviewed, by two physicians (S.B.W. and C.H.L.), blinded to MPI results, to validate the diagnosis of cardiac death and myocardial infarction. Myocardial injury after noncardiac surgery (MINS) was defined as a postoperative cardiac troponin concentration above the 99th percentile of the upper reference limit of the assay without evidence of nonischemic etiology among patients who underwent a routine troponin test after noncardiac surgery. Definitions of the study outcomes are provided in the Supplement Appendix.

Statistical Analysis

Baseline characteristics of the patients are reported as frequencies and percentages for categorical variables and means with standard deviations for continuous variables. Survival was assessed using the Kaplan–Meier method and compared using the log-rank test. We compared the primary and secondary outcomes according to the MPI results by using logistic regression models, and the final multivariable models included age, sex, the RCRI, and MPI results. These covariates were selected a priori based on previous evidence. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were reported. We assessed the risk prediction and stratification performance of MPI by calculating the area under the time-

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

dependent receiver operating characteristic (ROC) curve and the continuous net reclassification improvement (NRI). Because of the potential for type I error due to multiple comparisons, for which we did not adjust for the P values, results of analyses for secondary outcomes should be interpreted as exploratory. All reported P values are two-sided. A P value <.05 was considered statistically significant. Analyses were performed using R software, version 4.2.1 (R Foundation for Statistical Computing, Vienna, Austria). **Results Characteristics of the Population** From January 2000 to December 2021, 82,441 patients who underwent MPI for preoperative cardiac risk assessment before elective noncardiac surgery were included in this study, of whom 5603 (6.8%) had an abnormal MPI (Figure 1). The patients' mean age was 65.7±9.6 years, 57.5% were men, 50.2% underwent high-risk surgery, and 12.2% had an RCRI score ≥2 (Table 1). Compared with patients with normal MPI, patients with abnormal MPI were more likely to have comorbidities. The frequency of abnormal MPI increased as the RCRI score increased, ranging from 2.4% among patients with an RCRI 0 to 50.3% in patients with RCRI \geq 4 (Figure 2). **Primary and Secondary Outcomes** At 30 days, 82388 (99.9%) of patients were completed clinical follow-up. The primary outcomes (the composite of cardiac death or myocardial infarction) occurred in 184 patients (97 cardiac deaths and 100 myocardial infarctions) within 30 days of elective noncardiac surgery. The causes of death are summarized in eTable 1. Figure 3 demonstrates that the

cumulative incidences of the primary and secondary outcomes were all significantly higher among patients with abnormal MPI results than among those with normal results. As summarized in Table 2, the risk of the primary outcome was significantly higher in patients with abnormal MPI than in those with normal results (crude incidence, 1.2% vs 0.1%; adjusted OR, 4.64; 95% CI, 3.29 to 6.50; P<.001). Similarly, cardiac death (0.5% vs 0.1%; adjusted OR, 3.11; 95% CI, 1.86 to 5.07; P<.001), death from any cause (1.0% vs 0.5%; adjusted OR, 1.41; 95% CI, 1.03 to 1.89; P=.026), and myocardial infarction (0.9% vs 0.1%; adjusted OR, 8.19; 95% CI, 5.21 to 12.87; P<.001) were more frequent in patients with abnormal MPI. Among 23934 patients who underwent routine troponin testing after noncardiac surgery, the risk of MINS was also significantly higher in patients with abnormal MPI (16.5% vs 13.2%; adjusted OR, 1.37; 95% CI, 1.23 to 1.52; P<.001), as indicated in Table 2 and eFigure 1. When abnormal MPI findings were classified as fixed only or reversible, the primary outcome more frequently occurred among patients with a fixed defect only (adjusted OR, 3.42; 95% CI, 1.94 to 5.69; P<.001) and those with a reversible perfusion defect (adjusted OR, 5.26; 95% CI, 3.62 to 7.57; P<.001) than it did among patients with normal MPI, as demonstrated in eFigure 2A and eTable 2. In addition, the risk of the primary outcome increased according to the extent of ischemia. Compared with <5% ischemic burden (reference category), the adjusted OR for 5-10% ischemic burden was 1.47 (95% CI, 0.94 to 2.23; P=0.080), while >10% ischemic burden was associated with an adjusted OR of 3.52 (95% CI, 2.07 to 5.70; *P*<.001) (eFigure 2B and eTable 2).

Subgroup Analysis

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

Figure 4 demonstrates the incidence of the primary and secondary outcomes according to the RCRI score. The risk of cardiac death or MI increased with increasing RCRI score. The prognostic impact of an abnormal MPI on the risk of cardiac death or MI was more prominent in patients with low RCRI risk category (P for interaction <.001). Nevertheless, even among the highest risk group (patients with RCRI ≥2 and abnormal MPI), the absolute risk of cardiac death or MI was only 1.5% at 30 days. Additional subgroup analyses according to the clinical subgroup and types of surgery, which consistently showed the higher risk of primary outcome in patients with abnormal MPI, were summarized in eFigure 3 and eFigure 4. Prognostic Performance of MPI before Noncardiac Surgery The presence of an abnormal MPI improved discrimination for the primary outcome (AUC with MPI vs without MPI [0.77 vs 0.73; P < 0.001]) and significantly increased NRI (0.26,95% CI, 0.11-0.40; P<0.001). These significant improvements were driven mainly by improved discrimination for myocardial infarction. The model including adjustment for abnormal MPI results yielded good discrimination performance for myocardial infarction (AUC=0.83).Coronary Angiography and Revascularization before Noncardiac Surgery Among patients with abnormal MPI results (n=5603), 1743 underwent coronary angiography, and subsequently, 378 underwent coronary revascularization (260 percutaneous coronary interventions and 118 coronary artery bypass graft surgeries) before elective noncardiac surgery. Among patients with abnormal MPI, patient who underwent coronary

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

angiography or revascularization were not significantly associated with the lower risk of the primary outcome within 30 days of noncardiac surgery (Figure 5). Discussion This large, observational study identified a significant association between an abnormal preoperative MPI and the composite of cardiac death or myocardial infarction within 30 days of noncardiac surgery—an association that increased progressively according to the extent of myocardial ischemia. When compared with standard clinical risk factors, the use of preoperative MPI testing led to a significant improvement in discrimination as well as substantial reclassification of risk as assessed by the net reclassification index. Nonetheless, given the low overall incidence of post-operative cardiac events in the study population, the positive predictive value of an abnormal MPI study to predict postoperative cardiac event was low (1.2%), leading to potentially unnecessary coronary angiography and revascularization procedures with unproven prognostic value. Previous studies have examined a role for MPI in stratification of perioperative cardiac risk, but the results have been mixed. 5,23-25 A meta-analysis of nine studies including 1,179 patients undergoing noncardiac vascular surgery revealed that reversible defects in >20% of myocardial segments were significantly associated with perioperative complications.⁵ Another study suggested that incorporation of MPI may improve perioperative risk assessment of patients with obstructive disease upon coronary computed tomography angiography.²³ However, other studies have shown that routine use of MPI before abdominal aortic surgery did not predict the risk of cardiac complications^{26,27} and did not improve patient risk classification beyond essential assessment using age, RCRI, and surgical

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

priority.²⁸ However, These previous studies were limited by relatively small sample sizes and low event rates, inclusion of mainly patients undergoing relatively high-risk vascular surgery, and the use of outdated perfusion imaging techniques and perioperative management. 15,29 In contrast, our study included the largest population to date and included a broad spectrum of patients and surgical procedures across the full risk spectrum, thus demonstrating the consistent prognostic utility of MPI for predicting perioperative cardiac risk in contemporary practice. Current clinical guidelines do not support the routine use of MPI in preoperative risk assessment and rather recommend a subjective assessment of functional capacity as an initial step for preoperative cardiac risk assessment. 9,30 Typically, preoperative MPI is recommended only for patients with both elevated risk of major adverse cardiac events and poor exercise capacity. However, a recent prospective cohort study has revealed that subjective assessments of functional capacity are neither an accurate predictors of exercise capacity based on formal cardiopulmonary testing nor associated with the risk of post-operative cardiac events.²² Moreover, recent studies suggested that the prevalence of poor functional capacity is relatively low in clinical practice, and the most patients who experience postoperative cardiac complications had satisfactory preoperative functional capacities. 31-33 Therefore, our study suggested that more liberal use of MPI, ungated by functional capacity, is seemingly warranted, particularly in patients with a considerable surgical risk. Prior to our study, there was little information on the value of preoperative noninvasive stress testing in low-risk patients. 24,29 Our study, which included 32498 patients with RCRI 0, demonstrated that even among low-risk patients, an abnormal MPI study was significantly associated with an increased risk of post-operative cardiac events. In addition,

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

the prognostic impact of abnormal MPI was more prominent in patients with low cardiac risk. Nonetheless, given that the incidence of an abnormal MPI in low-risk patients (RCRI 0) was only 2.4% and the incidence of cardiac death or MI among these individuals was only 1.0%, the value of routine preoperative MPI testing in low-risk population should be interpreted in the context of the appropriate use of medical resources and cost-effectiveness in real practice. The original justification for preoperative MPI was to identify patients with significant myocardial ischemia who would potentially benefit from coronary revascularization prior to noncardiac surgery. However, this hypothesis was refuted by the randomized trials which demonstrated no clinical benefit of coronary revascularization before noncardiac surgery³⁴⁻³⁷ - results that are reinforced by our observational data. Therefore, our study suggested that preoperative MPI should not be the sole indication for preoperative invasive coronary angiography and subsequent coronary revascularization in stable elective surgical candidates, which is supported by recent randomized trial in patients with stable ischemic heart disease.³⁸ Nonetheless, previous observational study has suggested an association between performing preoperative MPI and reduced rate of perioperative mortality after noncardiac surgery.²⁹ These findings suggest that clinical benefits associated with preoperative MPI may be explained by mechanisms other than coronary revascularization such as careful anesthesiologic care, meticulous perioperative medical surveillance and management, changes in surgical technique, mostly towards a less invasive approach, or even deferring surgery in some very high risk patients. Further prospective study is necessary to evaluate whether performing preoperative MPI and subsequent changes in surgical and medical management of patient would improve postoperative cardiac outcomes. Our study has several limitations. First, it was a retrospective observational study.

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

Therefore, the possibility of residual confounding in the associations cannot be eliminated despite the statistical adjustments we made for several key clinical characteristics. Second, our data sources did not capture information on exercise tolerance. Third, biomarkers for perioperative myocardial necrosis were not obtained for all patients. Fourth, the attending physicians and surgeons were not blinded to the MPI results, which might have affected the clinical outcomes. Fifth, this study was performed in a tertiary hospital with high surgical volumes, thus limiting its generalizability to lower-volume surgical centers. In conclusion, among patients undergoing elective noncardiac surgery and referred for preoperative MPI testing, an abnormal MPI study was associated with an increased risk of 30-day cardiac death or MI—a result that was independent of age, sex, and clinical risk factors. However, the value of routine preoperative MPI testing appears to be limited given its low positive predictive value and the fact that coronary angiography or revascularization triggered by an abnormal MPI result was not associated with improved outcomes. Sources of Funding This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HC19C0022). **Role of the funding source** The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Disclosures

353

354 The authors have no conflicts to declare.

References

- 356 1. Weiser TG, Regenbogen SE, Thompson KD, Haynes AB, Lipsitz SR, Berry WR, Gawande AA.
 357 An estimation of the global volume of surgery: a modelling strategy based on available
- 358 data. *Lancet*. 2008;372:139-144. doi: 10.1016/S0140-6736(08)60878-8
- 359 2. Weiser TG, Haynes AB, Molina G, Lipsitz SR, Esquivel MM, Uribe-Leitz T, Fu R, Azad T, Chao
- 360 TE, Berry WR, et al. Estimate of the global volume of surgery in 2012: an assessment
- supporting improved health outcomes. *Lancet.* 2015;385 Suppl 2:S11. doi: 10.1016/s0140-
- 362 6736(15)60806-6
- 363 3. Spence J, LeManach Y, Chan MTV, Wang CY, Sigamani A, Xavier D, Pearse R, Alonso-Coello
- P, Garutti I, Srinathan SK, et al. Association between complications and death within 30
- days after noncardiac surgery. *Cmaj.* 2019;191:E830-e837. doi: 10.1503/cmaj.190221
- 366 4. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, De Hert S, de Laval I,
- Geisler T, Hinterbuchner L, et al. 2022 ESC Guidelines on cardiovascular assessment and
- management of patients undergoing non-cardiac surgery. *Eur Heart J.* 2022;43:3826-3924.
- doi: 10.1093/eurheartj/ehac270
- 5. Etchells E, Meade M, Tomlinson G, Cook D. Semiquantitative dipyridamole myocardial
- 371 stress perfusion imaging for cardiac risk assessment before noncardiac vascular surgery: a
- 372 meta-analysis. J Vasc Surg. 2002;36:534-540. doi: 10.1067/mva.2002.126563
- 373 6. Kristensen SD, Knuuti J, Saraste A, Anker S, Botker HE, Hert SD, Ford I, Gonzalez-Juanatey
- 374 JR, Gorenek B, Heyndrickx GR, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery:
- 375 cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery:
- 376 cardiovascular assessment and management of the European Society of Cardiology (ESC)
- and the European Society of Anaesthesiology (ESA). Eur Heart J. 2014;35:2383-2431. doi:
- 378 10.1093/eurheartj/ehu282
- 7. Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, Davila-
- Roman VG, Gerhard-Herman MD, Holly TA, Kane GC, et al. 2014 ACC/AHA guideline on
- perioperative cardiovascular evaluation and management of patients undergoing
- 382 noncardiac surgery: a report of the American College of Cardiology/American Heart
- Association Task Force on practice guidelines. J Am Coll Cardiol. 2014;64:e77-137. doi:
- 384 10.1016/j.jacc.2014.07.944
- 385 8. Devereaux PJ, Sessler DI. Cardiac Complications in Patients Undergoing Major Noncardiac
- 386 Surgery. N Engl J Med. 2015;373:2258-2269. doi: 10.1056/NEJMra1502824
- 387 9. Smilowitz NR, Berger JS. Perioperative Cardiovascular Risk Assessment and Management
- for Noncardiac Surgery: A Review. *JAMA*. 2020;324:279-290. doi: 10.1001/jama.2020.7840
- 389 10. Wijeysundera DN, Beattie WS, Austin PC, Hux JE, Laupacis A. Non-invasive cardiac stress
- 390 testing before elective major non-cardiac surgery: population based cohort study. *Bmj.*

- 391 2010;340:b5526. doi: 10.1136/bmj.b5526
- 392 11. Schulman-Marcus J, Feldman DN, Rao SV, Prasad A, McCoy L, Garratt K, Kim LK, Minutello
- 393 RM, Wong SC, Vora AN, et al. Characteristics of Patients Undergoing Cardiac
- 394 Catheterization Before Noncardiac Surgery: A Report From the National Cardiovascular
- Data Registry CathPCI Registry. JAMA Intern Med. 2016;176:611-618. doi:
- 396 10.1001/jamainternmed.2016.0259
- 397 12. Chan K, Abou-Zamzam AM, Woo K. Preoperative Cardiac Stress Testing in the Southern
- 398 California Vascular Outcomes Improvement Collaborative. Ann Vasc Surg. 2018;49:234-240.
- 399 doi: 10.1016/j.avsg.2017.11.028
- 400 13. Shin SY, Lyu Y, Shin Y, Choi HJ, Park J, Kim WS, Lee JH. Lessons Learned from Development
- 401 of De-identification System for Biomedical Research in a Korean Tertiary Hospital. *Healthc*
- 402 *Inform Res.* 2013;19:102-109. doi: 10.4258/hir.2013.19.2.102
- 403 14. Korean standard classification of diseases and causes of death (KCD-7).
- https://kssc.kostat.go.kr:8443/ksscNew_web/ekssc/main/main.do. Accessed 1 Apr 2016.
- 405 15. Smilowitz NR, Gupta N, Ramakrishna H, Guo Y, Berger JS, Bangalore S. Perioperative Major
- 406 Adverse Cardiovascular and Cerebrovascular Events Associated With Noncardiac Surgery.
- 407 *JAMA Cardiol.* 2017;2:181-187. doi: 10.1001/jamacardio.2016.4792
- 408 16. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, De Hert S, de Laval I,
- Geisler T, Hinterbuchner L, et al. 2022 ESC Guidelines on cardiovascular assessment and
- 410 management of patients undergoing non-cardiac surgery: Developed by the task force for
- 411 cardiovascular assessment and management of patients undergoing non-cardiac surgery
- 412 of the European Society of Cardiology (ESC) Endorsed by the European Society of
- 413 Anaesthesiology and Intensive Care (ESAIC). European Heart Journal. 2022;43:3826-3924.
- 414 doi: 10.1093/eurheartj/ehac270
- 415 17. Kim YH, Ahn JM, Park DW, Song HG, Lee JY, Kim WJ, Yun SC, Kang SJ, Lee SW, Lee CW, et
- 416 al. Impact of ischemia-guided revascularization with myocardial perfusion imaging for
- 417 patients with multivessel coronary disease. J Am Coll Cardiol. 2012;60:181-190. doi:
- 418 10.1016/j.jacc.2012.02.061
- 419 18. Hachamovitch R, Rozanski A, Shaw LJ, Stone GW, Thomson LE, Friedman JD, Hayes SW,
- 420 Cohen I, Germano G, Berman DS. Impact of ischaemia and scar on the therapeutic benefit
- derived from myocardial revascularization vs. medical therapy among patients undergoing
- 422 stress-rest myocardial perfusion scintigraphy. Eur Heart J. 2011;32:1012-1024. doi:
- 423 10.1093/eurheartj/ehg500
- 424 19. Dorbala S, Ananthasubramaniam K, Armstrong IS, Chareonthaitawee P, DePuey EG, Einstein
- 425 AJ, Gropler RJ, Holly TA, Mahmarian JJ, Park MA, et al. Single Photon Emission Computed
- 426 Tomography (SPECT) Myocardial Perfusion Imaging Guidelines: Instrumentation,
- 427 Acquisition, Processing, and Interpretation. J Nucl Cardiol. 2018;25:1784-1846. doi:

428	10.1007/s12350-018-1283-y

- 429 20. Son JS, Choi S, Kim K, Kim SM, Choi D, Lee G, Jeong SM, Park SY, Kim YY, Yun JM, et al.
- Association of Blood Pressure Classification in Korean Young Adults According to the 2017
- 431 American College of Cardiology/American Heart Association Guidelines With Subsequent
- 432 Cardiovascular Disease Events. *Jama*. 2018;320:1783-1792. doi: 10.1001/jama.2018.16501
- 433 21. Ruetzler K, Smilowitz NR, Berger JS, Devereaux PJ, Maron BA, Newby LK, de Jesus Perez V,
- Sessler DI, Wijeysundera DN. Diagnosis and Management of Patients With Myocardial
- 435 Injury After Noncardiac Surgery: A Scientific Statement From the American Heart
- 436 Association. *Circulation*. 2021;144:e287-e305. doi: 10.1161/CIR.000000000001024
- 437 22. Wijeysundera DN, Pearse RM, Shulman MA, Abbott TEF, Torres E, Ambosta A, Croal BL,
- 438 Granton JT, Thorpe KE, Grocott MPW, et al. Assessment of functional capacity before major
- 439 non-cardiac surgery: an international, prospective cohort study. *The Lancet*.
- 440 2018;391:2631-2640. doi: 10.1016/s0140-6736(18)31131-0
- 441 23. Dowsley TF, Sheth T, Chow BJW. Complementary pre-operative risk assessment using
- 442 coronary computed tomography angiography and nuclear myocardial perfusion imaging
- in non-cardiac surgery: A VISION-CTA sub-study. J Nucl Cardiol. 2020;27:1331-1337. doi:
- 444 10.1007/s12350-019-01779-9
- 445 24. Hashimoto J, Nakahara T, Bai J, Kitamura N, Kasamatsu T, Kubo A. Preoperative risk
- stratification with myocardial perfusion imaging in intermediate and low-risk non-cardiac
- 447 surgery. *Circ J.* 2007;71:1395-1400. doi: 10.1253/circj.71.1395
- 448 25. Metz LD, Beattie M, Hom R, Redberg RF, Grady D, Fleischmann KE. The prognostic value of
- normal exercise myocardial perfusion imaging and exercise echocardiography: a meta-
- 450 analysis. J Am Coll Cardiol. 2007;49:227-237. doi: 10.1016/j.jacc.2006.08.048
- 451 26. Baron JF, Mundler O, Bertrand M, Vicaut E, Barré E, Godet G, Samama CM, Coriat P, Kieffer
- 452 E, Viars P. Dipyridamole-thallium scintigraphy and gated radionuclide angiography to
- 453 assess cardiac risk before abdominal aortic surgery. *N Engl J Med.* 1994;330:663-669. doi:
- 454 10.1056/nejm199403103301002
- 455 27. Shin S, Kwon TW, Cho YP, Lee JY, Park H, Han Y. Preoperative cardiac evaluation by
- 456 dipyridamole thallium-201 myocardial perfusion scan provides no benefit in patients with
- 457 abdominal aortic aneurysm. World J Surg. 2013;37:2965-2971. doi: 10.1007/s00268-013-
- 458 2200-9
- 459 28. Yao Y, Quirk T, French M, Dharmalingam A, Collins N. Myocardial perfusion imaging failed
- 460 to improve patient risk classification compared with the revised cardiac risk index for early
- cardiac complications after major non-cardiac surgery. *Intern Med J.* 2022;52:1203-1214.
- 462 doi: 10.1111/imj.15662
- 463 29. Weinstein H, Steingart R. Myocardial perfusion imaging for preoperative risk stratification.
- 464 *J Nucl Med.* 2011;52:750-760. doi: 10.2967/jnumed.110.076158

465 30. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, De Hert S, de Laval I, 466 Geisler T, Hinterbuchner L, et al. 2022 ESC Guidelines on cardiovascular assessment and 467 management of patients undergoing non-cardiac surgery. Eur Heart J. 2022;43:3826-3924. 468 doi: 10.1093/eurheartj/ehac270 469 31. Gupta PK, Gupta H, Sundaram A, Kaushik M, Fang X, Miller WJ, Esterbrooks DJ, Hunter CB, 470 Pipinos, II, Johanning JM, et al. Development and validation of a risk calculator for 471 prediction of cardiac risk after surgery. Circulation. 2011;124:381-387. doi: 472 10.1161/circulationaha.110.015701 473 32. Biccard B. Proposed research plan for the derivation of a new Cardiac Risk Index. Anesth 474 Analg. 2015;120:543-553. doi: 10.1213/ane.000000000000598 475 33. Biccard BM. The clinical utility of preoperative functional assessment. Lancet. 476 2018;391:2580-2581. doi: 10.1016/s0140-6736(18)31375-8 477 34. McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, Pierpont G, Santilli S, 478 Rapp J, Hattler B, et al. Coronary-artery revascularization before elective major vascular 479 surgery. N Engl J Med. 2004;351:2795-2804. doi: 10.1056/NEJMoa041905 480 35. Hawn MT, Graham LA, Richman JS, Itani KM, Henderson WG, Maddox TM. Risk of major 481 adverse cardiac events following noncardiac surgery in patients with coronary stents. Jama. 482 2013;310:1462-1472. doi: 10.1001/jama.2013.278787 Poldermans D, Schouten O, Vidakovic R, Bax JJ, Thomson IR, Hoeks SE, Feringa HH, 483 36. 484 Dunkelgrün M, de Jaegere P, Maat A, et al. A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: 485 486 the DECREASE-V Pilot Study. J Am Coll Cardiol. 2007;49:1763-1769. doi: 487 10.1016/j.jacc.2006.11.052 488 37. Muthappan P, Smith D, Aronow HD, Eagle K, Wohns D, Fox J, Share D, Gurm HS. The 489 epidemiology and outcomes of percutaneous coronary intervention before high-risk 490 noncardiac surgery in contemporary practice: insights from the Blue Cross Blue Shield of 491 Michigan Cardiovascular Consortium (BMC2) Registry. J Am Heart Assoc. 2014;3:e000388. 492 doi: 10.1161/jaha.113.000388 493 38. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, Chaitman BR, 494 Senior R, López-Sendón J, Alexander KP, et al. Initial Invasive or Conservative Strategy for

Stable Coronary Disease. N Engl J Med. 2020;382:1395-1407. doi: 10.1056/NEJMoa1915922

495

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

MPI, myocardial perfusion imaging.

Figure legends Figure 1. Flow Diagram of Participants in the Study MPI, myocardial perfusion imaging. Figure 2. Frequency of Abnormal MPI According to the Revised Cardiac Risk Index MPI, myocardial perfusion imaging. Figure 3. Primary and Secondary Outcomes The cumulative incidences of the primary outcome of the composite of cardiac death and myocardial infarction (A) and the secondary outcomes of cardiac death (B), all-cause death (C), and myocardial infarction (D) within 30 days of noncardiac surgery. The P value was calculated by means of the log-rank test. Figure 4. Primary and Secondary Outcomes According to Revised Cardiac Risk Index Score Subgroup analyses by revised cardiac risk index score for primary and secondary outcomes, classified into three groups (score of 0, 1, and \geq 2). The crude incidence of the outcomes is marked on the bars. P value for interaction is also shown. Figure 5. Primary Outcome According to Preoperative Coronary Angiography and Revascularization among Patients with Abnormal MPI Results Cumulative incidences of the primary outcome of the composite of cardiac death and myocardial infarction within 30 days after noncardiac surgery. CAG, coronary angiography;

Table 1. Baseline Characteristics

		Myocardial perfusion imaging			
Characteristics	All patients	Abnormal	Normal	P value	
	(N = 82441)	(n = 5603)	(n = 76838)		
Age, mean (SD), years	65.7 (9.6)	67.5 (9.1)	65.5 (9.6)	<.001	
≥75 years	14581 (17.7)	1254 (22.4)	13327 (17.3)	<.001	
≥65 years	47926 (58.1)	3685 (65.8)	44241 (57.6)	<.001	
Sex (male)	47417 (57.5)	4500 (80.3)	42917 (55.9)	<.001	
BMI, mean (SD), kg/m ²	24.4 (3.4)	24.5 (3.4)	24.4 (3.5)	<.001	
Not available	2302 (2.8)	202 (3.6)	2100 (2.7)		
Hypertension	42570 (51.6)	3580 (63.9)	38990 (50.7)	<.001	
Diabetes	22295 (27.0)	2291 (40.9)	20004 (26.0)	<.001	
Insulin usage	3968 (4.8)	545 (9.7)	3423 (4.5)	<.001	
Hyperlipidemia	5407 (6.6)	670 (12.0)	4737 (6.2)	<.001	
Chronic kidney disease	4646 (5.6)	564 (10.1)	4082 (5.3)	<.001	
Creatinine >2.0 mg/dL	3696 (4.5)	394 (7.0)	3302 (4.3)	<.001	
Chronic heart failure	1462 (1.8)	373 (6.7)	1089 (1.4)	<.001	
Cerebrovascular disease	3248 (3.9)	491 (8.8)	2757 (3.6)	<.001	
Ischemic heart disease	8218 (10.0)	3360 (60.0)	4858 (6.3)	<.001	
High-risk surgery	41396 (50.2)	2775 (49.5)	38621 (50.3)	.29	
Type of surgery			, ,	<.001	
General	33652 (40.8)	2380 (42.5)	31272 (40.7)		
Thoracic	5959 (7.2)	387 (6.9)	5572 (7.3)		
Transplant	5566 (6.8)	207 (3.7)	5359 (7.0)		
Vascular	2345 (2.8)	451 (8.0)	1894 (2.5)		
Urologic	7779 (9.4)	758 (13.5)	7021 (9.1)		
Breast and endocrine	947 (1.1)	67 (1.2)	880 (1.1)		
Neurosurgery	11106 (13.5)	427 (7.6)	10679 (13.9)		
Obstetrics and gynecology	2361 (2.9)	57 (1.0)	2304 (3.0)		
Orthopedic	10849 (13.2)	674 (12.0)	10175 (13.2)		
Otolaryngology	1492 (1.8)	136 (2.4)	1356 (1.8)		
Plastic	385 (0.5)	59 (1.1)	326 (0.4)		
Left ventricular ejection					
fraction					
≤ 40%	712 (0.9)	349 (6.2)	363 (0.5)	<.001	
Not available	7342 (8.9)	218 (3.9)	7124 (9.3)		
Revised cardiac risk index				<.001	
0	32498 (39.4)	785 (14.0)	31713 (41.3)		
1	39837 (48.3)	2453 (43.8)	37384 (48.7)		
2	8445 (10.2)	1752 (31.3)	6693 (8.7)		
≥3	1661 (2.0)	613 (10.9)	1048 (1.4)		
Medication history*					
Beta blocker	16591 (20.1)	2862 (51.1)	13729 (17.9)	<.001	
Calcium channel blocker	38279 (46.4)	3693 (65.9)	34586 (45.0)	<.001	
ACEi or ARB	23904 (29.0)	2608 (46.5)	21296 (27.7)	<.001	

Statin	19981 (24.2)	3208 (57.3)	16773 (21.8)	<.001
Aspirin	9594 (11.6)	2684 (47.9)	6910 (9.0)	<.001
Clopidogrel	4896 (5.9)	1662 (29.7)	3234 (4.2)	<.001

- Data are presented as no. (%) of individuals unless otherwise indicated.
- *Medications at the time of admission for surgery.
- 520 Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor
- 521 blocker; SD, standard deviation.

Table 2. Thirty-day Outcomes, stratified by MPI Results

	Myocardial perfusion imaging ^a		Unadjusted		Adjusted ^b	
	Abnormal	Normal	OR [95% CI]	P value	OR [95% CI]	P value
	n=5598	n=76790				
Primary outcome						
Cardiac death or MI	$69(1.2)^{a}$	115 (0.1)	8.32 [6.14-11.19]	<.001	4.64 [3.29-6.50]	<.001
Secondary outcomes						
Cardiac death	26 (0.5)	71 (0.1)	5.04 [3.16-7.80]	<.001	3.11 [1.86-5.07]	<.001
All-cause death	58 (1.0)	352 (0.5)	2.27 [1.70-2.98]	<.001	1.41 [1.03-1.89]	.026
MI	52 (0.9)	48 (0.1)	15.0 [10.11-22.26]	<.001	8.19 [5.21-12.87]	<.001
Patients undergoing troponin test ^c	n=3281	n=20638				
Cardiac death and MINS	548 (16.7)	2741 (13.3)	1.31 [1.18-1.45]	<.001	1.38 [1.24-1.53]	<.001
MINS	542 (16.5)	2729 (13.2)	1.30 [1.17-1.44]	<.001	1.37 [1.23-1.52]	<.001

Abbreviations: CI, confidence interval; OR, odds ratio; MI, myocardial infarction; MINS, myocardial injury after noncardiac surgery.

^aCrude incidence within 30 days, no. of events (%).

b Adjusted variables were age, sex, revised cardiac risk index, and myocardial perfusion imaging result.

^cCardiac troponin test was conducted within 30 days after noncardiac surgery in 23934 patients, and 15 patients of them had missing data.


Table 3. Predictive Performance of Myocardial Perfusion Imaging before Noncardiac Surgery


·	·		Net reclassification improvement			
	AUC^{a}	P value	Events	Non-events	Overall [95% CI]	P value
Cardiac death and MI						
Baseline model ^b	0.73					
Plus MPI result	0.77	<.001	-0.12	0.38	0.26 [0.11-0.40]	<.001
Cardiac death						
Baseline model ^b	0.70					
Plus MPI result	0.73	.048	-0.26	0.35	0.09 [-0.10-0.28]	.360
All cause death					_	
Baseline model ^b	0.65					
Plus MPI result	0.65	.110	-0.42	0.30	-0.12 [-0.21-0.03]	.007
Myocardial infarction						
Baseline model ^b	0.76					
Plus MPI result	0.83	<.001	0.10	0.49	0.59 [0.39-0.79]	<.001


Abbreviations: AUC, area under the receiver-operating-characteristic curve; CI, confidence interval; MPI, myocardial perfusion imaging.


^aAUC for the relevant logistic regression model.


bCovariates in the baseline model were age, sex, and the revised cardiac risk index score.













B Cardiac death within 30 days after noncardiac surgery



C All cause death within 30 days after noncardiac surgery



D Myocardial infarction within 30 days after noncardiac surgery

